Loading
Physician who directs IQWiG, the German institute that produces the benefit assessments underpinning cancer drug pricing and coverage decisions.
Dr. med. Thomas Kaiser is Director of the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne. He previously headed IQWiG's Drug Assessment department and has been a central figure in Germany's early benefit assessment (AMNOG) process for new medicines, including oncology drugs. He publishes on evidence standards, surrogate endpoints and health technology assessment methodology.
| Title | Journal | Year |
|---|---|---|
| Weiterentwicklung und Vernetzung der onkologischen Versorgungsstrukturen, der Qualitätssicherung und der Forschung | Das Gesundheitswesen | 2022 |
Shares Gemeinsamer Bundesausschuss / IQWiG and the tags leadership, health technology assessment, regulation.
Shares the tags leadership, health technology assessment, regulation.
Shares the tags leadership, health technology assessment, regulation.
Shares the tags leadership, regulation.
Shares the tags leadership, regulation.
Shares the tags leadership, health technology assessment.
Shares the tags leadership, regulation.
Shares the tags leadership, regulation.